Clostridium difficile disease: Diagnosis, pathogenesis, and treatment update

Surgery (United States)

Volumn 162, Issue 2, 2017, Pages 325-348

  Napolitano, Lena M ^a   Edmiston, Charles E ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; GLUTAMATE DEHYDROGENASE; IMMUNOGLOBULIN;

BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; DIAGNOSTIC IMAGING; DIARRHEA; ENZYME IMMUNOASSAY; FECES MICROFLORA; FULMINANT COLITIS; HOSPITAL ADMISSION; HUMAN; INFECTION RISK; LABORATORY TEST; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; REVIEW; X-RAY COMPUTED TOMOGRAPHY; CASE REPORT; CLOSTRIDIUM INFECTIONS; MALE; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE;

CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 85014277530     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2017.01.018     Document Type: Review

References (154)

1. To, K.B., Napolitano, L.M., Clostridium difficile infection: update on diagnosis, epidemiology, and treatment strategies. Surg Infect (Larchmt) 15 (2014), 490–502.
2. Badger, V.O., Ledeboer, N.A., Graham, M.B., Edmiston, C.E. Jr., Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. JPEN J Parenter Enteral Nutr 36 (2012), 645–662.
3. Kuehn, B.M., Scientists seek strategies to prevent Clostridium difficile infections. JAMA 306 (2011), 1849–1850.
4. Nguyen, G.C., Kaplan, G.G., Harris, M.L., Brant, S.R., A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 103 (2008), 1443–1450.
5. Kelly, C.P., A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection. JAMA 30 (2009), 954–962.
6. Ananthakrishnan, A.N., McGinley, E.L., Binion, D.G., Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57 (2008), 205–210.
7. Ananthakrishnan, A.N., McGinley, E.L., Saeian, K., Binion, D.G., Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 17 (2011), 976–983.
8. Hospital stays involving C. difficile infections leveled after 300 percent increase since 1993. AHRQ News and Numbers, 2012, Agency for Healthcare Research, Rockville (MD) Available from: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf Accessed August 28, 2016.
9. Lessa, F.C., Mu, Y., Bamberg, W.M., Beldavs, Z.G., Dumyati, G.K., Dunn, J.R., et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 372 (2015), 825–834.
10. Leffler, D.A., Lamont, J.T., Clostridium difficile infection. N Engl J Med 372 (2015), 1539–1548.
11. Hunter, J.C., Mu, Y., Dumyati, G.K., Farley, M.M., Winston, L.G., Johnston, H.L., et al. Burden of nursing home-onset Clostridium difficile infection in the United States: estimates of incidence and patient outcomes. Open Forum Infect Dis, 3, 2016, ofv196.
12. Zerey, M., Paton, B.L., Lincourt, A.E., Gersin, K.S., Kercher, K.W., Heniford, B.T., The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt) 8 (2007), 557–566.
13. Halabi, W.J., Nguyen, V.Q., Carmichael, J.C., Pigazzi, A., Stamos, M.J., Mills, S., Clostridium difficile colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy. J Am Coll Surg 217 (2013), 802–812.
14. Zilberberg, M.D., Shorr, A.F., Kollef, M.H., Increase in adult Clostridium difficile-related hospitalizations and case-fatality rate, United States, 2000–2005. Emerg Infect Dis 14 (2008), 929–931.
15. Rao, K., Erb-Downward, J.R., Walk, S.T., Micic, D., Falkowski, N., Santhosh, K., et al. The systemic inflammatory response to Clostridium difficile infection. PLoS One, 9, 2014, e92578.
16. Hall, A.J., Curns, A.T., McDonald, L.C., Parashar, U.D., Lopman, B.A., The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. Clin Infect Dis 55 (2012), 216–223.
17. McDonald, L.C., Killgore, G.E., Thompson, A., Owens, R.C. Jr., Kazakova, S.V., Sambol, S.P., et al. An epidemic, toxin gene–variant strain of Clostridium difficile. N Engl J Med 353 (2005), 2433–2441.
18. Akerlund, T., Persson, I., Unemo, M., Norén, T., Svenungsson, B., Wullt, M., et al. Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J Clin Microbiol 46 (2008), 1530–1533.
19. Loo, V.G., Poirier, L., Miller, M.A., Oughton, M., Libman, M.D., Michaud, S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile–associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005), 2442–2449.
20. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 (2005), 1079–1084.
21. See, I., Mu, Y., Cohen, J., Beldavs, Z.G., Winston, L.G., Dumyati, G., et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis 58 (2014), 1394–1400.
22. Martin, J.S., Monaghan, T.M., Wilcox, M.H., Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol 13 (2016), 206–216.
23. Finney, J.M., Gastro-enterostomy for cicatrizing ulcer of the pylorus. Bull Johns Hopkins Hospital, 4, 1893, 53.
24. Wakefield, R.D., Sommers, S.D., Fatal membranous staphylococcal enteritis in surgical patients. Ann Surg, 138, 1953, 249.
25. Hummel, R.P., Altemeier, W.A., Hill, E.Q., Iatrogenic staphylococcal enterocolitis. Ann Surg, 160, 1964, 551.
26. Tedesco, F.J., Barton, R.W., Alpers, D.H., Clindamycin-associated colitis: a prospective study. Ann Intern Med 81 (1974), 429–433.
27. Gerding, D.N., Clostridium difficile 30 years on: what has, or has not, changed and why?. Int J Antimicrob Agents 33 (2009), S2–S8.
28. Rifkin, G.D., Fekety, F.R., Silva, J., Antibiotic-induced colitis implication of a toxin neutralized by Clostridium sordelli antitoxin. Lancet 2 (1977), 1103–1106.
29. Larson, H.E., Price, A.B., Pseudomembranous colitis: presence of clostridial toxin. Lancet 2 (1977), 1312–1314.
30. George, W.L., Sutter, V.L., Goldstein, E.J., Ludwig, S.L., Finegold, S.M., Etiology of antimicrobial-agent-associated colitis. Lancet 1 (1978), 802–803.
31. Larson, H.E., Price, A.B., Honour, P., Borriello, S.P., Clostridium difficile and the etiology of pseudomembranous colitis. Lancet 1 (1978), 1063–1066.
32. Deshpande, A., Pasupuleti, V., Thota, P., Pant, C., Rolston, D.D., Hernandez, A.V., et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 36 (2015), 452–460.
33. Tleyjeh, I.M., Bin Abdulhak, A.A., Riaz, M., Alasmari, F.A., Garbati, M.A., AlGhamdi, M., et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One, 7, 2012, e50836.
34. Janarthanan, S., Ditah, I., Adler, D.G., Ehrinpreis, M.N., Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 107 (2012), 1001–1010.
35. Kwok, C.S., Arthur, A.K., Anibueze, C.I., Singh, S., Cavallazzi, R., Loke, Y.K., Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 107 (2012), 1011–1019.
36. Shin, J.H., High, K.P., Warren, C.A., Older is not wiser, immunologically speaking: effect of aging on host response to Clostridium difficile infections. J Gerontol A Biol Sci Med Sci 71 (2016), 916–922.
37. Wijarnpreecha, K., Sornprom, S., Thongprayoon, C., Phatharacharukul, P., Cheungpasitporn, W., Nakkala, K., The risk of Clostridium difficile associated diarrhea in nasogastric tube insertion: a systematic review and meta-analysis. Dig Liver Dis 48 (2016), 468–472.
38. Phatharacharukul, P., Thongprayoon, C., Cheungpasitporn, W., Edmonds, P.J., Mahaparn, P., Bruminhent, J., The risks of incident and recurrent Clostridium difficile-associated diarrhea in chronic kidney disease and end-stage kidney disease patients: a systematic review and meta-analysis. Dig Dis Sci 60 (2015), 2913–2922.
39. Aquina, C.T., Probst, C.P., Becerra, A.Z., Hensley, B.J., Iannuzzi, J.C., Noyes, K., et al. High variability in nosocomial Clostridium difficile infection rates across hospitals after colorectal resection. Dis Colon Rectum 59 (2016), 323–331.
40. Donnelly, J.P., Wang, H.E., Locke, J.E., Mannon, R.B., Safford, M.M., Baddley, J.W., Hospital-onset Clostridium difficile infection among solid organ transplant recipients. Am J Transplant 15 (2015), 2970–2977.
41. Honda, H., Dubberke, E.R., Clostridium difficile infection in solid organ transplant recipients. Curr Opin Infect Dis 27 (2014), 336–341.
42. Eckburg, P.B., Bik, E.M., Berstein, C.N., Diversity of the human intestinal microbial flora. Science 5728 (2005), 1635–1638.
43. Kelly, C.P., Pothoulakis, C., LaMont, J.T., Clostridium difficile colitis. N Eng J Med 330 (1994), 257–262.
44. Noren, T., Clostridium difficile and the disease it causes. Mullany, P., Roberts, A.P., (eds.) Clostridium difficile, methods in molecular biology, 1st ed., 2010, Humana Press, Totowa (NJ), 9–35.
45. Leffeler, D.A., Lamont, J.T., Treatment of Clostridium difficile-associated disease. Gastroenterology 136 (2009), 1899–1912.
46. Blondeau, J.M., What have we learned about antimicrobial use and the risk of Clostridium difficile-associated diarrhea?. J Antimicrob Chemother 63 (2009), 238–242.
47. Carter, G.P., Rood, J.I., Lyras, D., The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol 20 (2012), 21–29.
48. Carroll, K.C., Bartlett, J.G., Biology of Clostridium difficile: implications for epidemiology and diagnosis. Annu Rev Microbiol 65 (2011), 501–522.
49. Jank, T., Aktories, K., Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol 16 (2008), 222–229.
50. Pothoulakis, C., Effects of Clostridium difficile toxins on epithelial cell barrier. Ann NY Acad Sci, 915, 2000, 347.
51. Sebaihia, M., Wren, B.W., Mullany, P., Fairweather, N.F., Minton, N., The multidrug resistant pathogen Clostridium difficile has a highly mobile mosaic genome. Nat Genet 38 (2006), 779–786.
52. Barbut, F., Jones, G., Eckert, C., Epidemiology and control of Clostridium difficile infections in healthcare settings; an update. Curr Opin Infect Dis 24 (2011), 370–376.
53. Cheknis, A.K., Sambol, S.P., Davidson, D.M., Distribution of Clostridium difficile strains with other strains froma a North American, European and Australian trial of treatment of C. difficile infections: 2005-2007. Anaerobe 15 (2009), 230–233.
54. Oka, K., Osaki, T., Hanawa, T., Kurata, S., Okazaki, M., Manzoku, T., et al. Molecular and microbiological characterization of Clostridium difficile isolates from single, relapse and reinfection. J Clin Microbiol 50 (2012), 915–921.
55. Onderdonk, A.B., Garrett, W.S., Gas gangrene and other Clostridium-associated diseases. Mandell, G.L., Bennett, J.E., Dolin, R., (eds.) Principles and practices of infectious diseases, 7th ed., 2010, Churchill Livingston, London, 3103–3110.
56. Stevens, D.L., Bryant, A.E., Berger, A., von Eichel-Streiber, C., Clostridium. Versalovic, J., Carroll, K., Funke, G., Jorgensen, J.H., Landry, M.L., Warnock, D.W., (eds.) Manual of clinical microbiology, 10th ed., 2011, ASM Press, Washington (DC), 834–857.
57. Kyne, L., Farrell, R.J., Kelly, C.P., Clostridium difficile. Gastroenterol Clin North Am 30 (2001), 753–777.
58. De Girolami, P.C., Hanff, P.A., Eichelberger, K., Longhi, L., Teresa, H., Pratt, J., et al. Multicenter evaluation of a new enzyme immunoassay for detection of Clostridium difficile enterotoxin A. J Clin Microbiol 30 (1992), 1085–1088.
59. Altaie, S.S., Meyer, P., Dryja, D., Comparison of two commercially available enzyme immunoassays for detection of Clostridium difficile in stool specimens. J Clin Microbiol 32 (1994), 51–53.
60. Song, L., Zhao, M., Duffy, D.C., Hansen, J., Shields, K., Wungliranirun, M., et al. Development and validation of direct enzyme-linked immunosorbent assays for ultrasensitive detection and quantification of Clostridium difficile toxin in stool. J Clin Microbiol 53 (2015), 3204–3212.
61. Eastwood, K., Else, P., Charlett, A., Wilcox, M., Comparison of nine commercially available Clostridium difficile toxin detection assays, a real-time PCR assay for C. difficile tcdB, and a glutamate dehydrogenase detection assay to cytotoxin testing and cytotoxigenic culture methods. J Clin Microbiol 47 (2009), 3211–3217.
62. Ticehurst, J.R., Aird, D.Z., Dam, L.M., Borek, A.P., Hargrove, J.T., Carroll, K.C., Effective detection of toxigenic Clostridium difficile by a two-step algorithm including tests for antigen and cytotoxin. J Clin Microbiol 44 (2006), 1145–1149.
63. Stamper, P.D., Alcabasa, R., Aird, D., Babiker, W., Wehrlin, J., Ikpeama, I., et al. Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples. J Clin Microbiol 47 (2009), 373–378.
64. Cohen, S.H., Gerding, D.N., Johnson, S., Kelly, C.P., Loo, V.G., McDonald, L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31 (2010), 431–455.
65. Polage, C.R., Gyorke, C.E., Kennedy, M.A., Leslie, J.L., Chin, D.L., Wang, S., et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Int Med 175 (2015), 1792–1801.
66. Fong, K.S., Fatica, C., Hall, G., Procop, G., Schindler, S., Gordon, S.M., et al. Impact of PCR testing for Clostridium difficile on incident rates and potential on public reporting: is the playing field level?. Infect Control Hosp Epidemiol 32 (2011), 932–933.
67. Macari, M., Balthazar, E.J., Megibow, A.J., The accordion sign at CT: a nonspecific finding in patients with colonic edema. Radiology 211 (1999), 743–746.
68. Ash, L., Baker, M.E., O'Malley, C.M. Jr., Gordon, S.M., Delaney, C.P., Obuchowski, N.A., Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. AJR Am J Roentgenol 186 (2006), 1393–1400.
69. Wee, B., Poels, J.A., McCafferty, I.J., Taniere, P., Olliff, J., A description of CT features of Clostridium difficile infection of the small bowel in four patients and a review of literature. Br J Radiol 82 (2009), 890–895.
70. Kawamoto, S., Horton, K.M., Fishman, E.K., Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. Radiographics 19 (1999), 887–897.
71. Ha, D., Tsai, C.J., Pneumatosis intestinalis in a patient with recurrent Clostridium difficile infection. BMJ Case Rep 2012 (2012), 1–4.
72. Kreiss, C., Forohar, F., Smithline, A.E., Brandt, L.J., Pneumatosis intestinalis complicating C. difficile pseudomembranous colitis. Am J Gastroenterol 94 (1999), 2560–2561.
73. Schenk, P., Madl, C., Kramer, L., Ratheiser, K., Kranz, A., Zauner, C., et al. Pneumatosis intestinalis with Clostridium difficile colitis as a cause of acute abdomen after lung transplantation. Dig Dis Sci 43 (1998), 2455–2458.
74. Gerding, D.N., Global epidemiology of Clostridium difficile infection in 2010. Infect Control Hosp Epidemiol 31 (2010), S32–S34.
75. Lo Vecchio, A., Zacur, G.M., Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 28 (2012), 1–9.
76. Vaishnavi, C., Clostridium difficile infection: clinical spectrum and approach to management. Indian J Gastroenterol 30 (2011), 245–254.
77. Vaishnavi, C., Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res 131 (2010), 487–499.
78. Hookman, P., Barkin, J.S., Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 15 (2009), 1554–1580.
79. Hurley, B.W., Nguyen, C.C., The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. Arch Intern Med 162 (2002), 2177–2184.
80. Heinlen, L., Ballard, J.D., Clostridium difficile infection. Am J Med Sci 340 (2010), 247–252.
81. Kachrimanidou, M., Malisiovas, N., Clostridium difficile infection: a comprehensive review. Crit Rev Microbiol 37 (2011), 178–187.
82. Rodemann, J.F., Dubberke, E.R., Reske, K.A., Seo da, H., Stone, C.D., Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 5 (2007), 339–344.
83. Lundeen, S.J., Otterson, M.F., Binion, D.G., Carman, E.T., Peppard, W.J., Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg 11 (2007), 138–142.
84. Yee, H.F. Jr., Brown, R.S. Jr., Ostroff, J.W., Fatal Clostridium difficile enteritis after total abdominal colectomy. J Clin Gastroenterol 22 (1996), 45–47.
85. Navaneethan, U., Venkatesh, P.G., Shen, B., Clostridium difficile infection and inflammatory bowel disease: Understanding the evolving relationship. World J Gastroenterol 16 (2010), 4892–4904.
86. Clayton, E.M., Rea, M.C., Shanahan, F., Quigley, E.M., Kiely, B., Hill, C., et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 104 (2009), 1162–1169.
87. Issa, M., Vijayapal, A., Graham, M.B., Beaulieu, D.B., Otterson, M.F., Lundeen, S., et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 5 (2007), 345–351.
88. Seril, D.N., Shen, B., Clostridium difficile infection in patients with ileal pouches. Am J Gastroenterol 109 (2014), 941–947.
89. Martinez Ugarte, M.L., Lightner, A.L., Colibaseanu, D., Khanna, S., Pardi, D.S., Dozois, E.J., et al. Clostridium difficile infection after restorative proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis. Colorectal Dis 18 (2016), O154–O157.
90. Weingarden, A.R., Chen, C., Zhang, N., Graiziger, C.T., Dosa, P.I., Steer, C.J., et al. Ursodeoxycholic acid inhibits Clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol 50 (2016), 624–630.
91. Drekonja, D.M., Butler, M., MacDonald, R., Bliss, D., Filice, G.A., Rector, T.S., et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 155 (2011), 839–847.
92. Di, X., Bai, N., Zhang, X., Liu, B., Ni, W., Wang, J., et al. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis 19 (2015), 339–349.
93. Louie, T.J., Byrne, B., Emery, J., Ward, L., Krulicki, W., Nguyen, D., et al. Differences of the fecal microflora with Clostridium difficile therapies. Clin Infect Dis 60:Suppl 2 (2015), S91–S97.
94. Bagdasarian, N., Rao, K., Malani, P.N., Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA 313 (2015), 398–408.
95. Dupont, H.L., Diagnosis and management of Clostridium difficile infection. Clin Gastroenterol Hepatol 11 (2013), 1216–1223 quiz e73.
96. Hecht, D.W., Galang, M.A., Sambol, S.P., Osmolski, J.R., Johnson, S., Gerding, D.N., In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrobial Agents Chemother 51 (2007), 2716–2719.
97. Shue, Y.K., Sears, P.S., Shangle, S., Walsh, R.B., Lee, C., Gorbach, S.L., et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 52 (2008), 1391–1395.
98. Louie, T.J., Emery, J., Krulicki, W., Byrne, B., Mah, M., OPT-80 eliminates Clostridium difficile and is sparing of Bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 53 (2009), 261–263.
99. Cornely, O.A., Nathwani, D., Ivanescu, C., Odufowora-Sita, O., Retsa, P., Odeyemi, I.A., Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother 69 (2014), 2892–2900.
100. Louie, T.J., Miller, M.A., Mullane, K.M., Weiss, K., Lentnek, A., Golan, Y., et al. OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364 (2011), 422–431.
101. Cornely, O.A., Crook, D.W., Esposito, R., Poirier, A., Somero, M.S., Weiss, K., et al., OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12 (2012), 281–289.
102. Surawicz, C.M., Brandt, L.J., Binion, D.G., Ananthakrishnan, A.N., Curry, S.R., Gilligan, P.H., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498.
103. Hussack, G., Tanha, J., An update on antibody-based immunotherapies for Clostridium difficile infection. Clin Exp Gastroenterol 9 (2016), 209–224.
104. Lowy, I., Molrine, D.C., Leav, B.A., Blair, B.M., Baxter, R., Gerding, D.N., et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362 (2010), 197–205.
105. Yang, Z., Ramsey, J., Hamza, T., Zhang, Y., Li, S., Yfantis, H.G., et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun 83 (2015), 822–831.
106. Wilcox, M.H., Gerding, D.N., Poxton, I.R., Kelly, C., Nathan, R., Birch, T., et al. MODIFY I and MODIFY II Investigators. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med 376 (2017), 305–317.
107. Traynor, K., Bezlotoxumab approved to prevent Clostridium difficile recurrence. Am J Health Syst Pharm, 73, 2016, 1902.
108. Markham, A., Bezlotoxumab: first global approval. Drugs 76 (2016), 1793–1798.
109. Knisely, J.M., Liu, B., Ranallo, R.T., Zou, L., Vaccines for healthcare-associated infections: promise and challenge. Clin Infect Dis 63 (2016), 657–662.
110. C diffense. Clostridium difficile vaccine trial [Internet], 2013, Sanofi, Paris Available from: http://www.cdiffense.org/home Accessed August 28, 2016.
111. Goldberg, E.J., Bhalodia, S., Jacob, S., Patel, H., Trinh, K.V., Varghese, B., et al. Clostridium difficile infection: a brief update on emerging therapies. Am J Health-Syst Pharm 72 (2015), 1007–1012.
112. Foglia, G., Shah, S., Luxemburger, C., Pietrobon, P.J., Clostridium difficile: development of a novel candidate vaccine. Vaccine 30 (2012), 4307–4309.
113. Sheldon, E., Kitchin, N., Peng, Y., Eiden, J., Gruber, W., Johnson, E., et al. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. Vaccine 34 (2016), 2082–2091.
114. Kociolek, L.K., Gerding, D.N., Breakthroughs in the treatment and prevention of Clostridium difficile infection. Nat Rev Gastroenterol Hepatol 13 (2016), 150–160.
115. Martin, J., Wilcox, M., New and emerging therapies for Clostridium difficile infection. Curr Opin Infect Dis 29 (2016), 546–554.
116. Osman, K.A., Ahmed, M.H., Hamad, M.A., Mathur, D., Emergency colectomy for fulminant Clostridium difficile colitis: striking the right balance. Scand J Gastroenterol 46 (2011), 1222–1227.
117. Synnott, K., Mealy, K., Merry, C., Kyne, L., Keane, C., Quill, R., Timing of surgery for fulminating pseudomembranous colitis. Br J Surg 85 (1998), 229–231.
118. Dudukgian, H., Sie, E., Gonzalez-Ruiz, C., Etzioni, D.A., Kaiser, A.M., C. difficile colitis–predictors of fatal outcome. J Gastrointest Surg 14 (2010), 315–322.
119. Stewart, D.B., Hollenbeak, C.S., Wilson, M.Z., Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review. Colorectal Dis 15 (2013), 798–804.
120. Bhangu, A., Nepogodiev, D., Gupta, A., Torrance, A., Singh, P., West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 99 (2012), 1501–1513.
121. Lee, D.Y., Chung, E.L., Guend, H., Whelan, R.L., Wedderburn, R.V., Rose, K.M., Predictors of mortality after emergency colectomy for Clostridium difficile colitis: an analysis of ACS-NSQIP. Ann Surg 259 (2014), 148–156.
122. Neal, M.D., Alverdy, J.C., Hall, D.E., Simmons, R.L., Zuckerbraun, B.S., Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 254 (2011), 423–427 discussion 427-9.
123. Lavallée, C., Laufer, B., Pépin, J., Mitchell, A., Dubé S., Labbé A.C., Fatal Clostridium difficile enteritis caused by the BI/NAP1/027 strain: a case series of ileal C. difficile infections. Clin Microbiol Infect 15 (2009), 1093–1099.
124. Pepin, J., Vancomycin for the treatment of Clostridium difficile infection: for whom is this expensive bullet really magic?. Clin Infect Dis 46 (2008), 1493–1498.
125. Johnson, S., Gerding, D.N., Fidaxomicin “chaser” regimen following vancomycin for patients with multiple Clostridium difficile recurrences. Clin Infect Dis 56 (2013), 309–310.
126. Soriano, M.M., Danziger, L.H., Gerding, D.N., Johnson, S., Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies. Open Forum Infect Dis, 1, 2014, ofu069.
127. Drekonja, D., Reich, J., Gezahegn, S., Greer, N., Shaukat, A., MacDonald, R., et al. Fecal microbiota transplantation for Clostridium difficile infection: a systematic review. Ann Intern Med 162 (2015), 630–638.
128. Kelly, C.R., Khoruts, A., Staley, C., Sadowsky, M.J., Abd, M., Alani, M., et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med 165 (2016), 609–616.
129. Fischer, M., Kao, D., Mehta, S.R., Martin, T., Dimitry, J., Keshteli, A.H., et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol 111 (2016), 1024–1031.
130. Aroniadis, O.C., Brandt, L.J., Greenberg, A., Borody, T., Kelly, C.R., Mellow, M., et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 50 (2016), 398–402.
131. AGA receives NIH funding for first national FMT registry [Internet], 2017, SLACK Incorporated, Thorofare (NJ) Available from: http://www.healio.com/gastroenterology/therapeutics-diagnostics/news/online/%7B5f73d4ea-3380-45eb-94c6-f00d5000bb58%7D/aga-receives-nih-funding-for-first-national-fmt-registry?utm_source=maestro&utm_medium=email&utm_campaign=gastroenterology%20news Accessed August 28, 2016.
132. Goldenberg, J.Z., Ma, S.S., Saxton, J.D., Martzen, M.R., Vandvik, P.O., Thorlund, K., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev, 2013, CD006095.
133. Pillai, A., Nelson, R.L., Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev, 2008, CD004611.
134. Griffin, A.T., Arnold, F.W., The most effective treatments for Clostridium difficile diarrhea: an evidence-based review. Infect Dis Clin Pract 19 (2011), 171–181.
135. McFarland, L.V., Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16 (2010), 2202–2222.
136. Leal, J.R., Heitman, S.J., Conly, J., Henderson, E.A., Manns, B.J., Cost-effective analysis of use of priobiotics for the prevention of Clostridium difficile-associated diarrhea in a provincial healthcare system. Infect Control Hosp Epidemiol 37 (2016), 1079–1086.
137. Siegel, J.D., Rhinehart, E., Jackson, M., Chiarello, L., Health Care Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 35 (2007), S65–S164.
138. Weber, D.J., Rutala, W.A., The role of the environment in transmission of Clostridium difficile infection in healthcare facilities. Infect Control Hosp Epidemiol 32 (2011), 207–209.
139. Gerding, D.N., Muto, C.A., Owens, R.C., Measures to control and prevent Clostridium difficile infection. Clin Infect Dis 46 (2008), S43–S49.
140. Loo, V.G., Environmental interventions to control Clostridium difficile. Infect Dis Clin North Am 29 (2015), 83–91.
141. Barbut, F., How to eradicate Clostridium difficile from the environment. J Hosp Infect 89 (2015), 287–295.
142. Goldstein, E.J., Johnson, S., Maziade, P.J., McFarland, L.V., Trick, W., Dresser, L., et al. Pathway to prevention of nosocomial Clostridium difficile infection. Clin Infect Dis 60:Suppl 2 (2015), S148–S158.
143. Bartlett, J.G., A call to arms: the imperative for antimicrobial stewardship. Clin Infect Dis 53 (2011), S4–S7.
144. Rebmann, T., Carrico, R.M., Association for Professionals in Infection Control and Epidemiology. Preventing Clostridium difficile infections: an executive summary of the association for professionals in infection control and epidemiology's elimination guide. Am J Infect Control 39 (2011), 239–242.
145. Lee, S., Prasad, P., Lin, M., Garritson, S., Nichols, A., Liu, C., Ertapenem prophylaxis associated with increased risk of Clostridium difficile infection in surgical patients. Infect Control Hosp Epidemiol 36 (2015), 1351–1354.
146. Li, X., Wilson, M., Nylander, W., Smith, T., Lynn, M., Gunnar, W., Analysis of morbidity and mortality outcomes in postoperative Clostridium difficile infection in the Veterans Health Administration. JAMA Surg 151 (2016), 314–322.
147. Bui, C., Zhu, E., Donnelley, M.A., Wilson, M.D., Morita, M., Cohen, S.H., et al. Antimicrobial stewardship programs that target only high-cost, broad-spectrum antimicrobials miss opportunities to reduce Clostridium difficile infections. Am J Infect Control 44 (2016), 1684–1686.
148. Gerding, D.N., Lessa, F.C., The epidemiology of Clostridium difficile infection inside and outside health care institutions. Infect Dis Clin North Am 29 (2015), 37–50.
149. Debast, S.B., Bauer, M.P., Kuijper, E.J., European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20:Suppl 2 (2014), 1–26.
150. Ferrada, P., Velopulos, C.G., Sultan, S., Haut, E.R., Johnson, E., Praba-Egge, A., et al. Timing and type of surgical treatment of Clostridium difficile-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg 76 (2014), 1484–1493 Erratum in: J Trauma Acute Care Surg 2014;77:186.
151. Sartelli, M., Malangoni, M.A., Abu-Zidan, F.M., Griffiths, E.A., Di Bella, S., McFarland, L.V., et al. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg, 10, 2015, 38.
152. Steele, S.R., McCormick, J., Melton, G.B., Paquette, I., Rivadeneira, D.E., Stewart, D., et al. Practice parameters for the management of Clostridium difficile infection. Dis Colon Rectum 58 (2015), 10–24.
153. Trubiano, J.A., Cheng, A.C., Korman, T.M., Roder, C., Campbell, A., May, M.L., et al. Australasian Society of Infectious Diseases updated guidelines for the management of Clostridium difficile infection in adults and children in Australia and New Zealand. Intern Med J 46 (2016), 479–493.
154. Cheng, A.C., Ferguson, J.K., Richards, M.J., Robson, J.M., Gilbert, G.L., McGregor, A., et al. Australasian society for infectious diseases guidelines for the diagnosis and treatment of Clostridium difficile infection. Med J Aust 194 (2011), 353–358.